SuperworthMonte Rosa Therapeutics market cap GLUE
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $924.8M
- Highest close in our data
- $2.1B
- Jul 2026
Monte Rosa Therapeutics is worth $924.8M at the close on Oct 23, 2026, at $10.84 a share.
That is up 34% over the last year and down 15% over five years.
Its highest close in our data was $2.1B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $924.8M | $831M | $2.1B | −18% |
| 2025 | $1.1B | $243M | $1.1B | +160% |
| 2024 | $433.3M | $183.4M | $635.8M | +53% |
| 2023 | $283M | $135.3M | $401.3M | −23% |
| 2022 | $368.3M | $321.5M | $792.9M | −61% |
| 2021 | $949.7M | $757.1M | $2B | n/a |
Against its peers
Companies in Biotechnology nearest Monte Rosa Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| GLUEMonte Rosa Therapeutics | $924.8M |
| MGTXMeiraGTx | $884.6M |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| PLXProtalix BioTherapeutics | $205.5M |
| KRYSKrystal Biotech | $9.2B |
| Peer median | $2.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Monte Rosa Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.